Neomycin sulfate [AC41]is an antibiotic that helps suppress normal bacterial flora of the bowel. The drug is meant to be taken in conjunction with erythromycin. Patients often take this drug pairing prior to having bowel surgeries to limit the amount of intestinal bacteria present.
Neomycin Sulfate also proves to be an affective adjunctive therapy for hepatic coma by reducing the ammonia-forming bacteria in the intestinal tract.
The drug will be available in 500 mg strength and is expected to launch in the next few months.
More articles on supply chain:
FDA strengthens warnings for two diabetes medications: 4 things to know
Batelle, Halyard to develop medical device wrap
FDA approves tool to detect hypoxia in brain
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
